Full-Time

Senior Clinical Trial Leader

Posted on 8/22/2025

Kura Oncology

Kura Oncology

201-500 employees

Clinical-stage oncology company develops targeted therapies

Compensation Overview

$177.9k - $204.4k/yr

+ Bonus + Equity

Boston, MA, USA

Hybrid

Hybrid on-site in Boston two days per week; travel up to 30% may be required.

Category
Biology & Biotech (2)
,
Requirements
  • Advanced degree desirable; PM certification desirable
  • Ideally 10 years clinical research experience with at least 5 years of direct trial management experience
  • Some experience in oncology preferred
  • Experience in CRO oversight is required
  • Manages large sized global clinical trial team
  • Works with minimal or no supervision
  • Ability to mentor junior staff
  • Self-directed and proactive handles multiple complex tasks
  • Strong organization, documentation, and communication skills
  • Excellent interpersonal skills: ability to collaborate across disciplines
  • Detailed knowledge of Good Clinical Practice (GCP), International Conference on Harmonisation (ICH) Guidelines and current US Food and Drug Administration regulations
  • Ability to travel up to approximately 30% of time
  • Hybrid on-site in Boston two days per week
Responsibilities
  • Responsible for the planning and management of the operational aspects of clinical trials, including CRO and vendor management/oversight, ensuring project milestones and objectives are met and clinical study deliverables are consistent with program/company goals
  • Collaborate with internal and external team members for the planning and execution of clinical trials
  • Accountable for coordination of planning, initiation, completion, and reporting of clinical study protocols within or across programs from team endorsement to reporting
  • Ensure clinical trials meet time, quality, and cost targets consistent with the overall Clinical Development Plan
  • Lead the development of and provide input into study-related documents, including ICFs, CRFs, monitoring plans, study, lab and pharmacy manuals, data management plans, etc. Also performs review and provides strong operational input in the development of clinical trial protocols and CSRs
  • Contribute to department documentation development, such as the development and writing of Standard Operating Procedures (SOPs)
  • Collaborate with Legal & Clinical Contracting & Outsourcing on the development and management of study specific agreements/budgets
  • Organize and manage project timelines and budgets; help ensure project deliverables are on time and within budget
  • Provides leadership and contributes to all operational aspects of the trial budget, including forecasts to ensure delivery within the business financial standards
  • Oversee the conduct of studies and ensure studies are implemented according to the study protocols and in compliance with local, ICH, GCP and company policies and procedures
  • Monitor and visit clinical study sites as needed
  • Track, collect, and review clinical documentation for clinical trials
  • Complete other duties as assigned by the manager
  • Key contributor to the development of annual trial/project objectives and communicating to relevant line management and Clinical Strategy Team (CST)
  • Serves as the key CST point of contact for the trial
  • Accountable for the successful preparation and presentation of operational content at key leadership discussions
  • Ensures strong oversight, review, and delivery of trial/project Corrective and Preventive Actions (CAPAs) to meet corporate compliance standards and timelines
  • Accountable for partnering with CRO in audit responses and addressing quality issues
  • Filters, prioritizes, analyzes, and validates complex and dynamic information from a diverse range of external and internal sources to respond to technical operational and organizational challenges
  • Ensures inspection readiness application for all assigned clinical trials
  • Manages projects/work streams with high complexity, risk, impact, and reach
  • Coordinates stakeholders from closely related areas and beyond
  • Demonstrates skills in successfully leading international teams in the matrix organization
  • Develop and lead operational and therapeutic area training for internal and external study team members
  • Directs multiple studies in parallel and/or be called upon for program management duties
  • Exhibits Subject Matter Expert level understanding of multiple functions and functional processes
  • Accountable for successful project execution including definition of milestones and clarification of project scope
  • Receives minimal guidance and works independently
  • Acts as a senior advisor and mentor within the team and beyond
Desired Qualifications
  • Advanced degree desirable; PM certification desirable
  • Hybrid on-site in Boston two days per week

Kura Oncology develops precision medicines for cancer, focusing on small-molecule drugs that target tumors with specific genetic mutations. It is in the clinical-stage, researching and developing its own drug candidates to eventually bring them to market. Its leading candidate, ziftomenib, blocks the menin-KMT2A/MLL protein interaction, offering a targeted approach for genetically defined acute myeloid leukemia (AML). The company is also pursuing tipifarnib for head and neck squamous cell carcinoma (HNSCC) and other solid tumors. By collaborating with academic institutions and other biotech companies, Kura Oncology expands its pipeline and advances therapies through clinical trials. The goal is to deliver effective, targeted cancer treatments for patients with unmet medical needs and to grow its portfolio through research, development, and partnerships.

Company Size

201-500

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • KOMET-017 Phase 3 frontline data 2026-2028 expands $400M R/R market to $7B total AML.
  • Darlifarnib plus cabozantinib addresses 200,000+ patient RCC opportunity with synergistic preclinical activity.
  • 84% private payer coverage and NCCN Category 2A listing drive rapid KOMZIFTI adoption.

What critics are saying

  • Syndax revumenib captures dominant U.S. market share, limiting KOMZIFTI Q1 2026 revenue growth.
  • KOMET-017 Phase 3 fails primary endpoints, blocking frontline expansion and accelerating cash burn.
  • Kyowa Kirin's KK2260 menin inhibitor erodes Kura's regional exclusivity in Asian markets.

What makes Kura Oncology unique

  • KOMZIFTI approved November 2025 with lower differentiation syndrome rates versus Syndax revumenib.
  • Ziftomenib advancing across 50% of AML subtypes including NPM1-m, KMT2A-r, FLT3-m mutations.
  • Kyowa Kirin partnership provides $667M cash plus $180M anticipated payments through Phase 3 2028.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Paid Paternity/Maternity Leave

Home Office Stipend

Lifestyle Spending Stipend

Commuter Stipend

Wellness Program

Gym Membership

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Mar 6th, 2026
Kura Oncology's Komzifti generates $2.1M in first weeks, triggers $135M milestone

Kura Oncology launched Komzifti, generating $2.1 million in net product revenue in late 2025. The company achieved rapid market access with payers covering most private and insured lives pre-approval, supported by an NCCN Category 2A listing and its KuraConnect programme. The company is advancing ziftomenib through the registrational KOMET-017 programme for earlier-stage AML treatment and developing multiple combinations with venetoclax and FLT3 inhibitors. Key data updates are expected in the first half of 2026. The first commercial sale triggered a $135 million milestone payment. Kura ended 2025 with $667.2 million in cash, which management says will fund the ziftomenib programme through anticipated phase 3 results, despite a fourth-quarter net loss of $81 million.

Yahoo Finance
Mar 5th, 2026
Kura Oncology's Comzifty generates $2.1M in first product revenue, triggers $135M milestone payment

Kura Oncology reported its first product revenue of $2.1 million from Comzifty in late 2025, marking its transition to a commercial-stage biopharmaceutical company. The company secured $135 million in milestone payments from Kyowa Kirin following the first commercial sale. Comzifty achieved 84% private payer coverage within 90 days of launch and received NCCN Category 2A recommendation within one week of submission. The company secured patent protection through July 2044. Management is pursuing a "first-to-frontline" strategy, targeting the $350 million to $400 million relapsed/refractory NPM1 market as an entry point to the broader $7 billion US AML opportunity. Pivotal COMET-017 frontline trial data readouts are expected to support potential accelerated FDA approvals, with current cash reserves funding operations through Phase 3 results in 2028.

Yahoo Finance
Mar 5th, 2026
Kura Oncology reports $667M cash position to support AML drug development to Phase 3

Kura Oncology has reported early commercial momentum for KOMZIFTI (ziftomenib), its once-daily oral menin inhibitor for relapsed or refractory acute myeloid leukaemia with NPM1 mutations. The drug generated $2.1 million in net revenue during the fourth quarter of 2025, based on approximately five weeks of sales following FDA approval on 13 November. The company achieved approximately 80% private payer coverage within 90 days of launch, with policies aligned to the label without additional restrictions. FDA Orange Book patent listings extend to 2044, supporting long-term market exclusivity. Kura reported $667.2 million in cash, cash equivalents and short-term investments, with an additional $180 million in anticipated collaboration payments, including a $135 million milestone from Kyowa Kirin. The company expects multiple clinical data milestones in 2026 across its AML and solid tumour programmes.

Stock Titan
Dec 2nd, 2025
Kura Oncology receives $135M milestone payment from Kyowa Kirin after first US sale of KOMZIFTI

Kura Oncology has received a $135 million milestone payment from Kyowa Kirin following the first US commercial sale of KOMZIFTI™. The payment was triggered under the companies' collaboration and licence agreement. The milestone represents a significant commercial achievement for the partnership between the two pharmaceutical companies. KOMZIFTI has now entered the US market, marking an important step in the drug's commercialisation.

GlobeNewswire
Oct 24th, 2025
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Kura Oncology receives $30 million development milestone payment in ziftomenib AML program with Kyowa Kirin. - Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 million milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. Kura and Kyowa Kirin announced the launch of the KOMET-017 trials on September 29, 2025. KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Kura believes KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the therapeutic potential of ziftomenib and the KOMET-017 trial being the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contact

INACTIVE